514 related articles for article (PubMed ID: 30008371)
1. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
[TBL] [Abstract][Full Text] [Related]
2. Cancer Nanomedicine: Lessons for Immuno-Oncology.
Sengupta S
Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral immunotherapy: using the tumor as the remedy.
Marabelle A; Tselikas L; de Baere T; Houot R
Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
[TBL] [Abstract][Full Text] [Related]
4. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
Aikins ME; Xu C; Moon JJ
Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
[TBL] [Abstract][Full Text] [Related]
5. CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.
Kranz LM; Beck JD; Grunwitz C; Hotz C; Vormehr M; Diken M
Hum Vaccin Immunother; 2017 Oct; 13(10):2272-2279. PubMed ID: 28846471
[No Abstract] [Full Text] [Related]
6. Integration of nano drug-delivery system with cancer immunotherapy.
Nakamura T; Harashima H
Ther Deliv; 2017 Nov; 8(11):987-1000. PubMed ID: 29061103
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional nanoparticles for cancer immunotherapy.
Saleh T; Shojaosadati SA
Hum Vaccin Immunother; 2016 Jul; 12(7):1863-75. PubMed ID: 26901287
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics.
Grimaldi AM; Incoronato M; Salvatore M; Soricelli A
Nanomedicine (Lond); 2017 Oct; 12(19):2349-2365. PubMed ID: 28868980
[TBL] [Abstract][Full Text] [Related]
10. Targeting myeloid cells using nanoparticles to improve cancer immunotherapy.
Amoozgar Z; Goldberg MS
Adv Drug Deliv Rev; 2015 Aug; 91():38-51. PubMed ID: 25280471
[TBL] [Abstract][Full Text] [Related]
11. Are peptide vaccines viable in combination with other cancer immunotherapies?
Ohtake J; Sasada T
Future Oncol; 2017 Aug; 13(18):1577-1580. PubMed ID: 28776424
[No Abstract] [Full Text] [Related]
12. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
13. Next generation approaches for tumor vaccination.
Patel A; Kaufman HL; Disis ML
Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial prospects of nano-targeted chemoimmunotherapy.
Da Silva CG; Rueda F; Löwik CW; Ossendorp F; Cruz LJ
Biomaterials; 2016 Mar; 83():308-20. PubMed ID: 26796043
[TBL] [Abstract][Full Text] [Related]
15. Gold nanoparticle mediated cancer immunotherapy.
Almeida JP; Figueroa ER; Drezek RA
Nanomedicine; 2014 Apr; 10(3):503-14. PubMed ID: 24103304
[TBL] [Abstract][Full Text] [Related]
16. Immunosenescence and cancer.
Pawelec G
Biogerontology; 2017 Aug; 18(4):717-721. PubMed ID: 28220304
[TBL] [Abstract][Full Text] [Related]
17. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
Zhu G; Zhang F; Ni Q; Niu G; Chen X
ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
[TBL] [Abstract][Full Text] [Related]
18. 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.
Cappuccini F; Pollock E; Stribbling S; Hill AVS; Redchenko I
Oncotarget; 2017 Jul; 8(29):47474-47489. PubMed ID: 28537896
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy: the beginning of the end of cancer?
Farkona S; Diamandis EP; Blasutig IM
BMC Med; 2016 May; 14():73. PubMed ID: 27151159
[TBL] [Abstract][Full Text] [Related]
20. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]